Literature DB >> 22095099

Aldosterone and the heart: from basic research to clinical evidence.

C Catena1, G Colussi, L Marzano, L A Sechi.   

Abstract

Recent views suggest that long-term exposure to elevated aldosterone concentrations might result in cardiac, vascular, renal, and metabolic sequelae that occur independent of the blood pressure level. Indirect evidence of the untoward effects of aldosterone on the heart has been clearly established in clinical studies that have tested the effects of mineralocorticoid receptor antagonists in the treatment of systolic heart failure. As it has become clear in recent years, the interaction between aldosterone and the heart has to deal with additional actions of the hormone on specific cell types, cellular mechanisms, and molecules that are involved in regulation of tissue responses, leading to hypertrophy, remodeling, and fibrosis. The majority of these effects are mediated by activation of the mineralocorticoid receptors that are expressed in cardiomyocytes and cardiac fibroblasts, and mediate the genomic effects of the hormone. Evidence of interactions between aldosterone and the heart that occur independent of the renal effects of aldosterone, however, is not limited to the context of systolic heart failure and observations obtained in other disease states have led, together with findings of animal studies, to a better understanding of the potential benefits of aldosterone antagonists. In this narrative overview, we highlight the most recent findings that have been obtained in experimental animal models and in clinical conditions that include, in addition to systolic heart failure, primary aldosteronism, essential hypertension, diastolic heart failure, and arrhythmia. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095099     DOI: 10.1055/s-0031-1291318

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Authors:  Giuseppe Mulè; Emilio Nardi; Laura Guarino; Valentina Cacciatore; Giulio Geraci; Ilenia Calcaterra; Bruno Oddo; Francesco Vaccaro; Santina Cottone
Journal:  Hypertens Res       Date:  2015-01-08       Impact factor: 3.872

2.  Relationship of ocular microcirculation, measured by laser speckle flowgraphy, and silent brain infarction in primary aldosteronism.

Authors:  Hiroshi Kunikata; Naoko Aizawa; Masataka Kudo; Shunji Mugikura; Fumihiko Nitta; Ryo Morimoto; Yoshitsugu Iwakura; Yoshikiyo Ono; Fumitoshi Satoh; Hidetoshi Takahashi; Sadayoshi Ito; Shoki Takahashi; Toru Nakazawa
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

3.  Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans.

Authors:  Ervin R Fox; Solomon K Musani; Tandaw E Samdarshi; Jared K Taylor; Walter L Beard; Daniel F Sarpong; Vanessa Xanthakis; Eric E McClendon; Philip R Liebson; Thomas N Skelton; Kenneth R Butler; Thomas H Mosley; Herman Taylor; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2015-02-05       Impact factor: 5.501

Review 4.  Treatment of Primary Aldosteronism and Organ Protection.

Authors:  Cristiana Catena; GianLuca Colussi; Leonardo A Sechi
Journal:  Int J Endocrinol       Date:  2015-05-17       Impact factor: 3.257

5.  Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats.

Authors:  Hao Wang; Jewell A Jessup; Zhuo Zhao; Jaqueline Da Silva; Marina Lin; Lindsay M MacNamara; Sarfaraz Ahmad; Mark C Chappell; Carlos M Ferrario; Leanne Groban
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

Review 6.  Aldosterone and the heart: still an unresolved issue?

Authors:  Cristiana Catena; GianLuca Colussi; Francesca Nait; Flavia Martinis; Francesca Pezzutto; Leonardo A Sechi
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-14       Impact factor: 5.555

Review 7.  Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Hai-Ha Le; Chadia El-Khatib; Margaux Mombled; Frédéric Guitarian; Muaamar Al-Gobari; Mor Fall; Perrine Janiaud; Ivanny Marchant; Michel Cucherat; Théodora Bejan-Angoulvant; François Gueyffier
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

8.  RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.

Authors:  Ibrahim F Benter; Fawzi Babiker; Ibrahim Al-Rashdan; Mariam Yousif; Saghir Akhtar
Journal:  J Diabetes Res       Date:  2013-08-27       Impact factor: 4.011

9.  Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure.

Authors:  Adam Bress; Jin Han; Shitalben R Patel; Ankit A Desai; Ibrahim Mansour; Vicki Groo; Kristin Progar; Ebony Shah; Thomas D Stamos; Coady Wing; Joe G N Garcia; Rick Kittles; Larisa H Cavallari
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

10.  Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.

Authors:  Robert Holaj; Ján Rosa; Tomáš Zelinka; Branislav Štrauch; Ondřej Petrák; Tomáš Indra; Zuzana Šomlóová; David Michalský; Květoslav Novák; Dan Wichterle; Jiří Widimský
Journal:  J Hypertens       Date:  2015-04       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.